Warfarin therapy not warranted for secondary prevention of CVD

MOspace/Manakin Repository

Breadcrumbs Navigation

Warfarin therapy not warranted for secondary prevention of CVD

Please use this identifier to cite or link to this item: http://hdl.handle.net/10355/7655

[-] show simple item record

dc.contributor.author Wong, Long en_US
dc.contributor.author Criswell, Dan en_US
dc.date.accessioned 2010-06-14T16:06:13Z
dc.date.available 2010-06-14T16:06:13Z
dc.date.issued 2009-12
dc.identifier.citation Evidence Based Practice 12(12): 01-02. en_US
dc.identifier.uri http://hdl.handle.net/10355/7655
dc.description.abstract No data are available to support the addition or substitution of warfarin after failure of antiplatelet agents for secondary prevention of ischemic stroke. Further, warfarin may be no better than placebo at reducing the risk of noncardioembolic stroke. (Strength of recommendation [SOR] B, based on heterogeneous meta-analyses.) en_US
dc.language.iso en_US en_US
dc.publisher Family Physicians Inquiries Network en_US
dc.relation.ispartof Evidence Based Practice 12(12): 01-02. en_US
dc.subject thrombotic occlusion en_US
dc.subject aspirin therapy en_US
dc.subject.lcsh Thrombosis en_US
dc.subject.lcsh Aspirin -- Therapeutic use en_US
dc.title Warfarin therapy not warranted for secondary prevention of CVD en_US
dc.type Article en_US
dc.relation.ispartofcommunity University of Missouri-Columbia. School of Medicine. Department of Family and Community Medicine. Family Physicians Inquiries Network. Evidence Based Practice. en_US
dc.relation.ispartofcollection Evidence Based Practice, 2009 en_US


This item appears in the following Collection(s)

[-] show simple item record